| 1 | Rasopathy | Enrichment | HRAS, KRAS, MAP2K1, MAP2K2, MRAS, NRAS, RAF1, RRAS2, SOS1, SOS2 | 16.00 |
| 2 | Noonan syndrome 1 | Enrichment | BRAF, HRAS, KRAS, MAP2K1, MAP2K2, MRAS, NRAS, RAF1, RRAS, RRAS2, SOS1, SOS2 | 11.25 |
| 3 | Noonan syndrome and noonan-related syndrome | Enrichment | BRAF, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1, SOS1 | 10.89 |
| 4 | Lung non-small cell carcinoma | Enrichment | BRAF, EGFR, ERBB2, HRAS, KRAS, MAP2K1, NRAS | 9.77 |
| 5 | Leukoencephalopathy with vanishing white matter 1 | Enrichment | EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5 | 8.74 |
| 6 | Leukoencephalopathy with vanishing white matter 5 | Enrichment | EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5 | 8.32 |
| 7 | Cardiofaciocutaneous syndrome 1 | Enrichment | BRAF, KRAS, MAP2K1, MAP2K2 | 8.04 |
| 8 | Cardiofaciocutaneous syndrome | Enrichment | BRAF, KRAS, MAP2K1, MAP2K2 | 8.04 |
| 9 | Leukoencephalopathy with vanishing white matter | Enrichment | EIF2B1, EIF2B2, EIF2B3, EIF2B4, EIF2B5 | 7.97 |
| 10 | Pilomyxoid astrocytoma | Enrichment | BRAF, FGFR1, KRAS, NTRK2, RAF1 | 7.43 |
| 11 | Thyroid cancer, nonmedullary, 2 | Enrichment | BRAF, HRAS, NRAS, PTEN | 6.51 |
| 12 | Noonan syndrome 3 | Enrichment | HRAS, KRAS, RAF1, SOS1 | 6.51 |
| 13 | Follicular thyroid carcinoma | Enrichment | BRAF, HRAS, NRAS, PTEN | 6.51 |
| 14 | Melanocytic nevus syndrome, congenital | Enrichment | BRAF, HRAS, NRAS, RAF1 | 6.21 |
| 15 | Langerhans cell histiocytosis | Enrichment | BRAF, MAP2K1, NRAS | 6.03 |
| 16 | Lung cancer susceptibility 3 | Enrichment | ACTA2, BRAF, EGFR, ERBB2, KRAS | 5.50 |
| 17 | Nevus, epidermal | Enrichment | FGFR3, HRAS, KRAS, NRAS | 5.47 |
| 18 | Schimmelpenning-feuerstein-mims syndrome | Enrichment | HRAS, KRAS, NRAS | 5.43 |
| 19 | Breast implant-associated anaplastic large cell lymphoma | Enrichment | JAK1, JAK2, STAT3 | 5.24 |
| 20 | Auriculocondylar syndrome 1 | Enrichment | EDN1, GNAI3, PLCB4 | 5.12 |
| 21 | Autosomal dominant non-syndromic intellectual disability | Enrichment | CACNA1I, CACNG2, CAMK2A, CAMK2B, PPP3CA, YWHAZ | 5.03 |
| 22 | Hemimegalencephaly | Enrichment | AKT3, MTOR, PTEN | 5.03 |
| 23 | Long qt syndrome 1 | Enrichment | CACNA1C, CALM1, CALM2, CALM3, ITPR3 | 4.99 |
| 24 | Bladder cancer | Enrichment | EGFR, ERBB2, ERBB3, FGFR3, HRAS, KRAS | 4.97 |
| 25 | Differentiated thyroid carcinoma | Enrichment | BRAF, HRAS, KRAS, NRAS, NTRK1, NTRK3 | 4.97 |
| 26 | Loeys-dietz syndrome | Enrichment | TGFB2, TGFB3, TGFBR1, TGFBR2 | 4.92 |
| 27 | Catecholaminergic polymorphic ventricular tachycardia | Enrichment | CALM1, CALM2, CALM3 | 4.29 |
| 28 | Primary hypereosinophilic syndrome | Enrichment | FGFR1, PDGFRA, PDGFRB | 4.25 |
| 29 | Pulmonic stenosis | Enrichment | BRAF, SOS1 | 4.01 |
| 30 | Ras-associated autoimmune leukoproliferative disorder | Enrichment | KRAS, NRAS | 4.01 |
| 31 | Ectodermal dysplasia and immune deficiency | Enrichment | IKBKG, NFKBIA | 4.01 |
| 32 | Fetomaternal alloimmune thrombocytopenia 1 | Enrichment | ITGA2, ITGA2B, ITGB3 | 3.96 |
| 33 | Lung squamous cell carcinoma | Enrichment | EGFR, FGFR3, KRAS | 3.96 |
| 34 | Familial thoracic aortic aneurysm and aortic dissection | Enrichment | ACTA2, MYLK, TGFB2, TGFB3, TGFBR1, TGFBR2 | 3.90 |
| 35 | Pigmented nodular adrenocortical disease, primary, 1 | Enrichment | GNAS, PRKAR1A | 3.81 |
| 36 | Colorectal cancer | Enrichment | AKT1, BRAF, EP300, ERBB2, FGFR2, FGFR3, NRAS, PIK3R1 | 3.78 |
| 37 | Juvenile myelomonocytic leukemia | Enrichment | KRAS, NRAS, RRAS | 3.71 |
| 38 | Undetermined early-onset epileptic encephalopathy | Enrichment | CACNA1A, CACNA1B, CACNA2D1, PPP3CA, YWHAG | 3.65 |
| 39 | Long qt syndrome | Enrichment | CACNA1C, CACNA1S, CALM1, CALM2 | 3.63 |
| 40 | Lung cancer | Enrichment | ACTA2, BRAF, EGFR, ERBB2, KRAS | 3.61 |
| 41 | Neurodevelopmental disorder with hypotonia, language delay, and skeletal defects with or without seizures | Enrichment | CACNA1A, CACNA1C | 3.54 |
| 42 | Large congenital melanocytic nevus | Enrichment | HRAS, NRAS | 3.54 |
| 43 | Arteriovenous malformations of the brain | Enrichment | BRAF, EGFR, IL6, KRAS | 3.49 |
| 44 | Loeys-dietz syndrome 2 | Enrichment | TGFBR1, TGFBR2 | 3.49 |
| 45 | Pfeiffer syndrome | Enrichment | FGFR1, FGFR2 | 3.49 |
| 46 | Jackson-weiss syndrome | Enrichment | FGFR1, FGFR2 | 3.49 |
| 47 | Encephalocraniocutaneous lipomatosis | Enrichment | FGFR1, KRAS | 3.49 |
| 48 | Loeys-dietz syndrome 4 | Enrichment | TGFB2, TGFB3 | 3.49 |
| 49 | Baraitser-winter cerebrofrontofacial syndrome | Enrichment | ACTB, ACTG1 | 3.49 |
| 50 | Primary hyperaldosteronism | Enrichment | BRAF, CACNA1H, GNAS | 3.35 |
| 51 | Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi | Enrichment | GNA11, PIK3R1 | 3.34 |
| 52 | Megalencephaly-capillary malformation-polymicrogyria syndrome | Enrichment | AKT3, PIK3R2 | 3.24 |
| 53 | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1 | Enrichment | AKT3, PIK3R2 | 3.24 |
| 54 | Chronic myelogenous leukemia, bcr-abl1 positive | Enrichment | KRAS, NRAS | 3.24 |
| 55 | Noonan syndrome with multiple lentigines | Enrichment | BRAF, RAF1 | 3.24 |
| 56 | Heart disease | Enrichment | CREBBP, GATA4, NKX2-5 | 3.20 |
| 57 | 46,xy partial gonadal dysgenesis | Enrichment | GATA4, MAP3K1, SOS1 | 3.20 |
| 58 | Marfan syndrome | Enrichment | TGFB2, TGFBR1, TGFBR2 | 3.20 |
| 59 | Type 2 diabetes mellitus | Enrichment | AKT2, IRS1, IRS2, SLC2A4 | 3.12 |
| 60 | Diffuse gastric and lobular breast cancer syndrome | Enrichment | KRAS, MAP3K6 | 3.04 |
| 61 | Insulin-like growth factor i | Enrichment | IGF1, IGF1R | 3.02 |
| 62 | Crouzon syndrome | Enrichment | FGFR2, FGFR3 | 3.02 |
| 63 | Hyper-ige syndrome 1, autosomal dominant, with recurrent infections | Enrichment | ITGB3, STAT3 | 3.02 |
| 64 | Lacrimoauriculodentodigital syndrome 1 | Enrichment | FGFR2, FGFR3 | 3.02 |
| 65 | Bleeding disorder, platelet-type, 16 | Enrichment | ITGA2B, ITGB3 | 3.02 |
| 66 | Stuve-wiedemann syndrome 1 | Enrichment | IL6ST, LIFR | 3.02 |
| 67 | Tethered spinal cord syndrome | Enrichment | BRAF, CREBBP | 3.02 |
| 68 | Loeys-dietz syndrome 1 | Enrichment | TGFBR1, TGFBR2 | 3.02 |
| 69 | Spermatocytoma | Enrichment | FGFR3, HRAS | 3.02 |
| 70 | Anastomosing haemangioma | Enrichment | GNA11, GNA14 | 3.02 |
| 71 | Stüve-wiedemann syndrome | Enrichment | IL6ST, LIFR | 3.02 |
| 72 | Lip and oral cavity carcinoma | Enrichment | BRAF, EGFR, HRAS | 2.95 |
| 73 | Breast adenocarcinoma | Enrichment | AKT1, KRAS | 2.85 |
| 74 | Nk-cell enteropathy | Enrichment | ERBB4, IGF1R, JAK3 | 2.84 |
| 75 | Erythrocytosis, familial, 1 | Enrichment | EPOR, JAK2 | 2.72 |
| 76 | Megacystis-microcolon-intestinal hypoperistalsis syndrome 1 | Enrichment | ACTG2, MYLK | 2.72 |
| 77 | Saethre-chotzen syndrome | Enrichment | FGFR2, FGFR3 | 2.72 |
| 78 | Glioma | Enrichment | FGFR2, NTRK3 | 2.72 |
| 79 | Capillary malformation-arteriovenous malformation 1 | Enrichment | KRAS, MAP2K1 | 2.71 |
| 80 | Leukemia, chronic myeloid | Enrichment | KRAS, NRAS | 2.71 |
| 81 | Gallbladder cancer | Enrichment | BRAF, KRAS | 2.71 |
| 82 | Overgrowth syndrome | Enrichment | MTOR, PIK3R1 | 2.71 |
| 83 | Brugada syndrome | Enrichment | CACNA1C, CACNA2D1, CACNB2 | 2.68 |
| 84 | Rare genetic intellectual disability | Enrichment | CREBBP, EP300, MTOR | 2.65 |
| 85 | Melanoma, uveal | Enrichment | GNA11, PLCB4 | 2.65 |
| 86 | Rubinstein-taybi syndrome 1 | Enrichment | CREBBP, EP300 | 2.65 |
| 87 | Chromosome 16p13.3 deletion syndrome, proximal | Enrichment | CREBBP, EP300 | 2.65 |
| 88 | Ovarian cancer | Enrichment | AKT1, EGFR, ERBB2, KRAS, NTRK1, PDGFRA, RRAS2 | 2.64 |
| 89 | Gliosarcoma | Enrichment | EGFR, FGFR1, FGFR3 | 2.57 |
| 90 | Hemifacial hyperplasia | Enrichment | FGFR2, FGFR3 | 2.51 |
| 91 | Visceral myopathy 1 | Enrichment | ACTG2, MYLK | 2.51 |
| 92 | Giant cell glioblastoma | Enrichment | EGFR, FGFR1, FGFR3 | 2.49 |
| 93 | Myeloma, multiple | Enrichment | BRAF, CREBBP, FGFR3, KRAS, PIK3R2 | 2.49 |
| 94 | Arteriovenous malformation | Enrichment | HRAS, MAP2K1 | 2.48 |
| 95 | Cowden syndrome | Enrichment | AKT1, PTEN | 2.48 |
| 96 | Lennox-gastaut syndrome | Enrichment | CACNA1A, MAPK10 | 2.39 |
| 97 | Myopathy, x-linked, with excessive autophagy | Enrichment | HRAS, MAP2K1 | 2.38 |
| 98 | Melanoma | Enrichment | BRAF, PTEN | 2.38 |
| 99 | Diffuse large b-cell lymphoma | Enrichment | BRAF, CREBBP, STAT3 | 2.35 |
| 100 | Epidermolysis bullosa, junctional 5b, with pyloric atresia | Enrichment | ITGA6, ITGB4 | 2.34 |
| 101 | 46,xy disorder of sex development | Enrichment | FGFR3, INSR | 2.34 |
| 102 | Glycogen storage disease | Enrichment | GYS1, GYS2 | 2.30 |
| 103 | Specific learning disability | Enrichment | MAPK1, YWHAG | 2.30 |
| 104 | Cerebral palsy | Enrichment | CACNA1A, CACNA1C, GNB1, PDGFRB | 2.29 |
| 105 | Ellis-van creveld syndrome | Enrichment | PRKACA, PRKACB | 2.28 |
| 106 | Inflammatory bowel disease 1 | Enrichment | IL6, PRKCQ | 2.28 |
| 107 | Meningioma | Enrichment | AKT1, PTEN | 2.22 |
| 108 | Glanzmann thrombasthenia 1 | Enrichment | ITGA2B, ITGB3 | 2.20 |
| 109 | Breast cancer | Enrichment | AKT1, CACNA2D1, KRAS, PTEN | 2.19 |
| 110 | Congenital stationary night blindness | Enrichment | CACNA1F, CACNA2D4, GNB3 | 2.11 |
| 111 | Atrial heart septal defect | Enrichment | HDAC8, NKX2-5 | 2.10 |
| 112 | Interatrial communication | Enrichment | HDAC8, NKX2-5 | 2.10 |
| 113 | Cone-rod dystrophy 6 | Enrichment | CACNA1F, CACNA2D4 | 2.09 |
| 114 | Hereditary breast carcinoma | Enrichment | AKT1, KRAS, PTEN | 2.03 |
| 115 | Wilms tumor 1 | Enrichment | BRAF, IGF2 | 2.03 |
| 116 | Anhidrosis, isolated, with normal sweat glands | Enrichment | ITPR2 | 2.01 |
| 117 | Proteus syndrome | Enrichment | AKT1 | 2.01 |
| 118 | Thyrotoxic periodic paralysis 1 | Enrichment | CACNA1S | 2.01 |
| 119 | Hypoinsulinemic hypoglycemia with hemihypertrophy | Enrichment | AKT2 | 2.01 |
| 120 | Hypothyroidism, congenital, nongoitrous, 9 | Enrichment | IRS4 | 2.01 |
| 121 | Oculoectodermal syndrome | Enrichment | KRAS | 2.01 |
| 122 | Vacterl association with hydrocephalus | Enrichment | PTEN | 2.01 |
| 123 | Pallister-killian syndrome | Enrichment | ARAF | 2.01 |
| 124 | Incontinentia pigmenti | Enrichment | IKBKG | 2.01 |
| 125 | Autoinflammatory disease, systemic, x-linked | Enrichment | IKBKG | 2.01 |
| 126 | Noonan syndrome 5 | Enrichment | RAF1 | 2.01 |
| 127 | Noonan syndrome 4 | Enrichment | SOS1 | 2.01 |
| 128 | Epilepsy, idiopathic generalized 9 | Enrichment | CACNB4 | 2.01 |
| 129 | Brugada syndrome 4 | Enrichment | CACNB2 | 2.01 |
| 130 | Melorheostosis, isolated | Enrichment | MAP2K1 | 2.01 |
| 131 | Noonan syndrome 7 | Enrichment | BRAF | 2.01 |
| 132 | Leopard syndrome 3 | Enrichment | BRAF | 2.01 |
| 133 | Nail disorder, nonsyndromic congenital, 3 | Enrichment | PLCD1 | 2.01 |
| 134 | Cardiomyopathy, dilated, 1nn | Enrichment | RAF1 | 2.01 |
| 135 | Cardiofaciocutaneous syndrome 3 | Enrichment | MAP2K1 | 2.01 |
| 136 | Melanosis, neurocutaneous | Enrichment | NRAS | 2.01 |
| 137 | Noonan syndrome 9 | Enrichment | SOS2 | 2.01 |
| 138 | Noonan syndrome 6 | Enrichment | NRAS | 2.01 |
| 139 | Fetal encasement syndrome | Enrichment | CHUK | 2.01 |
| 140 | Episodic ataxia, type 5 | Enrichment | CACNB4 | 2.01 |
| 141 | Ataxia-oculomotor apraxia 3 | Enrichment | PIK3R5 | 2.01 |
| 142 | Noonan syndrome 11 | Enrichment | MRAS | 2.01 |
| 143 | Immunodeficiency 15b | Enrichment | IKBKB | 2.01 |
| 144 | Noonan syndrome 13 | Enrichment | MAPK1 | 2.01 |
| 145 | Spondylometaphyseal dysplasia with corneal dystrophy | Enrichment | PLCB3 | 2.01 |
| 146 | Leukoencephalopathy with vanishing white matter 3 | Enrichment | EIF2B3 | 2.01 |
| 147 | Immunodeficiency 15a | Enrichment | IKBKB | 2.01 |
| 148 | Charcot-marie-tooth disease, demyelinating, type 1j | Enrichment | ITPR3 | 2.01 |
| 149 | Neurodevelopmental disorder with speech impairment and with or without seizures | Enrichment | CACNA1I | 2.01 |
| 150 | Intellectual developmental disorder, autosomal recessive 63 | Enrichment | CAMK2A | 2.01 |
| 151 | Congenital myopathy 18 | Enrichment | CACNA1S | 2.01 |
| 152 | Developmental and epileptic encephalopathy 91 | Enrichment | PPP3CA | 2.01 |
| 153 | Intellectual developmental disorder, autosomal dominant 54 | Enrichment | CAMK2B | 2.01 |
| 154 | Arthrogryposis, cleft palate, craniosynostosis, and impaired intellectual development | Enrichment | PPP3CA | 2.01 |
| 155 | Short syndrome | Enrichment | PIK3R1 | 2.01 |
| 156 | Ectodermal dysplasia and immunodeficiency 1 | Enrichment | IKBKG | 2.01 |
| 157 | Immune dysregulation, autoimmunity, and autoinflammation | Enrichment | PLCG1 | 2.01 |
| 158 | Auriculocondylar syndrome 2a | Enrichment | PLCB4 | 2.01 |
| 159 | Cone-rod dystrophy, x-linked, 3 | Enrichment | CACNA1F | 2.01 |
| 160 | Autism 19 | Enrichment | EIF4E | 2.01 |
| 161 | Retinal cone dystrophy 4 | Enrichment | CACNA2D4 | 2.01 |
| 162 | Neurodevelopmental disorder with hypotonia, stereotypic hand movements, and impaired language | Enrichment | MEF2C | 2.01 |
| 163 | Papillary tumor of the pineal region | Enrichment | PTEN | 2.01 |
| 164 | Cardiofaciocutaneous syndrome 2 | Enrichment | KRAS | 2.01 |
| 165 | Primary aldosteronism, seizures, and neurologic abnormalities | Enrichment | CACNA1D | 2.01 |
| 166 | Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2 | Enrichment | AKT3 | 2.01 |
| 167 | Lymphangioma | Enrichment | BRAF | 2.01 |
| 168 | Brugada syndrome 3 | Enrichment | CACNA1C | 2.01 |
| 169 | Epilepsy, childhood absence 6 | Enrichment | CACNA1H | 2.01 |
| 170 | Malignant hyperthermia 5 | Enrichment | CACNA1S | 2.01 |
| 171 | Coronary artery disease, autosomal dominant, 1 | Enrichment | MEF2A | 2.01 |
| 172 | Phace association | Enrichment | BRAF | 2.01 |
| 173 | Melorheostosis | Enrichment | MAP2K1 | 2.01 |
| 174 | Leopard syndrome 2 | Enrichment | RAF1 | 2.01 |
| 175 | Intellectual developmental disorder, autosomal dominant 10 | Enrichment | CACNG2 | 2.01 |
| 176 | Sinoatrial node dysfunction and deafness | Enrichment | CACNA1D | 2.01 |
| 177 | Immunodeficiency 36 with lymphoproliferation | Enrichment | PIK3R1 | 2.01 |
| 178 | Cardiofaciocutaneous syndrome 4 | Enrichment | MAP2K2 | 2.01 |
| 179 | Autoinflammation, antibody deficiency, and immune dysregulation | Enrichment | PLCG2 | 2.01 |
| 180 | Long qt syndrome 16 | Enrichment | CALM3 | 2.01 |
| 181 | Cowden syndrome 6 | Enrichment | AKT1 | 2.01 |
| 182 | Agammaglobulinemia 7, autosomal recessive | Enrichment | PIK3R1 | 2.01 |
| 183 | Spinocerebellar ataxia 42 | Enrichment | CACNA1G | 2.01 |
| 184 | Developmental and epileptic encephalopathy 110 | Enrichment | CACNA2D1 | 2.01 |
| 185 | Glioma susceptibility 2 | Enrichment | PTEN | 2.01 |
| 186 | Familial cold autoinflammatory syndrome 3 | Enrichment | PLCG2 | 2.01 |
| 187 | Developmental and epileptic encephalopathy 56 | Enrichment | YWHAG | 2.01 |
| 188 | Spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits | Enrichment | CACNA1G | 2.01 |
| 189 | Developmental and epileptic encephalopathy 69 | Enrichment | CACNA1E | 2.01 |
| 190 | Hyperaldosteronism, familial, type iv | Enrichment | CACNA1H | 2.01 |
| 191 | Bartsocas-papas syndrome 2 | Enrichment | CHUK | 2.01 |
| 192 | Intellectual developmental disorder, autosomal dominant 53 | Enrichment | CAMK2A | 2.01 |
| 193 | Trigonitis | Enrichment | RAF1 | 2.01 |
| 194 | Auriculocondylar syndrome 2b | Enrichment | PLCB4 | 2.01 |
| 195 | Intellectual developmental disorder, autosomal dominant 59 | Enrichment | CAMK2G | 2.01 |
| 196 | Long qt syndrome 15 | Enrichment | CALM2 | 2.01 |
| 197 | Capillary hemangioma | Enrichment | AKT3 | 2.01 |
| 198 | Immunodeficiency 133 with ectodermal dysplasia with or without peripheral neuropathy | Enrichment | ITPR3 | 2.01 |
| 199 | Leukoencephalopathy with vanishing white matter 2 | Enrichment | EIF2B2 | 2.01 |
| 200 | 5q14.3 microdeletion syndrome | Enrichment | MEF2C | 2.01 |
| 201 | Conn's syndrome | Enrichment | CACNA1H | 2.01 |
| 202 | Congenital pulmonary airway malformation | Enrichment | KRAS | 2.01 |
| 203 | Complete atrioventricular septal defect without ventricular hypoplasia | Enrichment | MEF2C | 2.01 |
| 204 | Sporadic hemiplegic migraine | Enrichment | CACNA1A | 2.01 |
| 205 | Syringocystadenoma papilliferum | Enrichment | BRAF | 2.01 |
| 206 | Combined immunodeficiency-hypogammaglobulinemia-skeletal anomalies syndrome due to ikbka deficiency | Enrichment | CHUK | 2.01 |
| 207 | Atypical timothy syndrome | Enrichment | CACNA1C | 2.01 |
| 208 | Aldosterone-producing adenoma with seizures and neurological abnormalities | Enrichment | CACNA1D | 2.01 |
| 209 | Ganglioglioma | Enrichment | BRAF | 2.01 |
| 210 | Nongerminomatous germ cell tumor | Enrichment | BRAF | 2.01 |
| 211 | Phace syndrome | Enrichment | BRAF | 2.01 |
| 212 | Timothy syndrome type 2 | Enrichment | CACNA1C | 2.01 |
| 213 | Phakomatosis pigmentokeratotica | Enrichment | HRAS | 2.01 |
| 214 | Mef2c-related disorder | Enrichment | MEF2C | 2.01 |
| 215 | Segmental outgrowth-lipomatosis-arteriovenous malformation-epidermal nevus syndrome | Enrichment | PTEN | 2.01 |
| 216 | Periodic paralysis with transient compartment-like syndrome | Enrichment | CACNA1S | 2.01 |
| 217 | Classic hairy cell leukemia | Enrichment | BRAF | 2.01 |
| 218 | Timothy syndrome type 1 | Enrichment | CACNA1C | 2.01 |
| 219 | Distal 17p13.3 microdeletion syndrome | Enrichment | YWHAE | 2.01 |
| 220 | Inflammatory bowel disease-recurrent sinopulmonary infections syndrome | Enrichment | NFAT5 | 2.01 |
| 221 | Neurocutaneous melanocytosis | Enrichment | NRAS | 2.01 |
| 222 | Cacna1c-related disorders | Enrichment | CACNA1C | 2.01 |
| 223 | Akt2-related familial partial lipodystrophy | Enrichment | AKT2 | 2.01 |
| 224 | Benign paroxysmal torticollis of infancy | Enrichment | CACNA1A | 2.01 |
| 225 | Rhabdomyosarcoma | Enrichment | HRAS, PTEN | 1.97 |
| 226 | Neurodevelopmental disorder with dysmorphic facies and distal limb anomalies | Enrichment | CACNA1C, RAC1 | 1.97 |
| 227 | Junctional epidermolysis bullosa | Enrichment | ITGA6, ITGB4 | 1.97 |
| 228 | Aortic valve disease 1 | Enrichment | NKX2-5, SOS1 | 1.96 |
| 229 | Hypocalciuric hypercalcemia, familial, type ii | Enrichment | GNA11 | 1.90 |
| 230 | Atrial septal defect 7 with or without atrioventricular conduction defects | Enrichment | NKX2-5 | 1.90 |
| 231 | Acrodysostosis 1 with or without hormone resistance | Enrichment | PRKAR1A | 1.90 |
| 232 | Cardiospondylocarpofacial syndrome | Enrichment | MAP3K7 | 1.90 |
| 233 | Chondrodysplasia with platyspondyly, distinctive brachydactyly, hydrocephaly, and microphthalmia | Enrichment | HDAC6 | 1.90 |
| 234 | Hypothyroidism, congenital, nongoitrous, 5 | Enrichment | NKX2-5 | 1.90 |
| 235 | Pseudohypoparathyroidism, type ic | Enrichment | GNAS | 1.90 |
| 236 | Carney complex, type 1 | Enrichment | PRKAR1A | 1.90 |
| 237 | Osseous heteroplasia, progressive | Enrichment | GNAS | 1.90 |
| 238 | Deafness, autosomal recessive 44 | Enrichment | ADCY1 | 1.90 |
| 239 | 46,xy sex reversal 6 | Enrichment | MAP3K1 | 1.90 |
| 240 | Frontometaphyseal dysplasia 2 | Enrichment | MAP3K7 | 1.90 |
| 241 | Atrioventricular septal defect 4 | Enrichment | GATA4 | 1.90 |
| 242 | Autoimmune lymphoproliferative syndrome, type iii | Enrichment | PRKCD | 1.90 |
| 243 | Ventricular tachycardia, familial | Enrichment | GNAI2 | 1.90 |
| 244 | Acth-independent macronodular adrenal hyperplasia 1 | Enrichment | GNAS | 1.90 |
| 245 | Auriculocondylar syndrome 3 | Enrichment | EDN1 | 1.90 |
| 246 | Stuve-wiedemann syndrome 2 | Enrichment | IL6ST | 1.90 |
| 247 | Hyper-ige syndrome 4a, autosomal dominant, with recurrent infections | Enrichment | IL6ST | 1.90 |
| 248 | Pituitary adenoma 3, multiple types | Enrichment | GNAS | 1.90 |
| 249 | Auriculocondylar syndrome 4 | Enrichment | HDAC9 | 1.90 |
| 250 | Cornelia de lange syndrome 5 | Enrichment | HDAC8 | 1.90 |
| 251 | Cardioacrofacial dysplasia 2 | Enrichment | PRKACB | 1.90 |
| 252 | Neurodevelopmental disorder with hypotonia, impaired speech, and behavioral abnormalities | Enrichment | GNAI1 | 1.90 |
| 253 | Myxoma, intracardiac | Enrichment | PRKAR1A | 1.90 |
| 254 | Question mark ears, isolated | Enrichment | EDN1 | 1.90 |
| 255 | Spinocerebellar ataxia 14 | Enrichment | PRKCG | 1.90 |
| 256 | Atrial septal defect 2 | Enrichment | GATA4 | 1.90 |
| 257 | Ventricular septal defect 3 | Enrichment | NKX2-5 | 1.90 |
| 258 | Hypocalcemia, autosomal dominant 2 | Enrichment | GNA11 | 1.90 |
| 259 | Testicular anomalies with or without congenital heart disease | Enrichment | GATA4 | 1.90 |
| 260 | Pigmented nodular adrenocortical disease, primary, 4 | Enrichment | PRKACA | 1.90 |
| 261 | Disorders of gnas inactivation | Enrichment | GNAS | 1.90 |
| 262 | Hypoplastic left heart syndrome 2 | Enrichment | NKX2-5 | 1.90 |
| 263 | Congenital heart defects and ectodermal dysplasia | Enrichment | PRKD1 | 1.90 |
| 264 | Cardioacrofacial dysplasia 1 | Enrichment | PRKACA | 1.90 |
| 265 | Thrombocytopenia 6 | Enrichment | SRC | 1.90 |
| 266 | Hyper-ige syndrome 4b, autosomal recessive, with recurrent infections | Enrichment | IL6ST | 1.90 |
| 267 | 8p23.1 microdeletion syndrome | Enrichment | GATA4 | 1.90 |
| 268 | Immunodeficiency 94 with autoinflammation and dysmorphic facies | Enrichment | IL6ST | 1.90 |
| 269 | Menke-hennekam syndrome 1 | Enrichment | CREBBP | 1.90 |
| 270 | Rubinstein-taybi syndrome due to 16p13.3 microdeletion | Enrichment | CREBBP | 1.90 |
| 271 | Immunodeficiency 112 | Enrichment | MAP3K14 | 1.90 |
| 272 | Prkar1b-related neurodegenerative dementia with intermediate filaments | Enrichment | PRKAR1B | 1.90 |
| 273 | Aortic arch interruption | Enrichment | NKX2-5 | 1.90 |
| 274 | Cerebral cavernous malformations 5 | Enrichment | MAP3K3 | 1.90 |
| 275 | Atrial heart septal defect 7 | Enrichment | NKX2-5 | 1.90 |
| 276 | Partial atrioventricular septal defect with ventricular hypoplasia | Enrichment | GATA4 | 1.90 |
| 277 | Menke-hennekam syndrome | Enrichment | CREBBP | 1.90 |
| 278 | Monostotic fibrous dysplasia | Enrichment | GNAS | 1.90 |
| 279 | Phakomatosis cesiomarmorata | Enrichment | GNA11 | 1.90 |
| 280 | Malignant epithelial tumor of salivary glands | Enrichment | PRKD1 | 1.90 |
| 281 | Verrucous hemangioma | Enrichment | MAP3K3 | 1.90 |
| 282 | Mazabraud syndrome | Enrichment | GNAS | 1.90 |
| 283 | Nik deficiency | Enrichment | MAP3K14 | 1.90 |
| 284 | Autosomal dominant macrothrombocytopenia | Enrichment | ITGA2B, ITGB3 | 1.88 |
| 285 | Spastic ataxia | Enrichment | CACNA1G, CACNB4, ITPR1 | 1.81 |
| 286 | Hereditary breast ovarian cancer syndrome | Enrichment | EIF2B5, KRAS, PTEN | 1.77 |
| 287 | Non-immune hydrops fetalis | Enrichment | ACTA1, HRAS, KRAS | 1.75 |
| 288 | Erythroleukemia, familial | Enrichment | ERBB3 | 1.75 |
| 289 | Hypochondroplasia | Enrichment | FGFR3 | 1.75 |
| 290 | Beare-stevenson cutis gyrata syndrome | Enrichment | FGFR2 | 1.75 |
| 291 | Paget disease, extramammary | Enrichment | ERBB2 | 1.75 |
| 292 | Osteoglophonic dysplasia | Enrichment | FGFR1 | 1.75 |
| 293 | Thanatophoric dysplasia, type i | Enrichment | FGFR3 | 1.75 |
| 294 | Trigonocephaly 1 | Enrichment | FGFR1 | 1.75 |
| 295 | Donohue syndrome | Enrichment | INSR | 1.75 |
| 296 | Baraitser-winter syndrome 1 | Enrichment | ACTB | 1.75 |
| 297 | Muenke syndrome | Enrichment | FGFR3 | 1.75 |
| 298 | Premature aging syndrome, penttinen type | Enrichment | PDGFRB | 1.75 |
| 299 | Systemic lupus erythematosus 6 | Enrichment | ITGAM | 1.75 |
| 300 | Hyperinsulinemic hypoglycemia, familial, 5 | Enrichment | INSR | 1.75 |
| 301 | Pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities | Enrichment | INSR | 1.75 |
| 302 | Diabetes mellitus, insulin-resistant, with acanthosis nigricans | Enrichment | INSR | 1.75 |
| 303 | Hypereosinophilic syndrome, idiopathic | Enrichment | PDGFRA | 1.75 |
| 304 | Immunodeficiency 73a with defective neutrophil chemotaxis and leukocytosis | Enrichment | RAC2 | 1.75 |
| 305 | Scaphocephaly, maxillary retrusion, and impaired intellectual development | Enrichment | FGFR2 | 1.75 |
| 306 | Resting heart rate, variation in | Enrichment | ADRB1 | 1.75 |
| 307 | Congenital myopathy 2a, typical, autosomal dominant | Enrichment | ACTA1 | 1.75 |
| 308 | Apert syndrome | Enrichment | FGFR2 | 1.75 |
| 309 | Multiple self-healing squamous epithelioma | Enrichment | TGFBR1 | 1.75 |
| 310 | Mandibulofacial dysostosis with alopecia | Enrichment | EDNRA | 1.75 |
| 311 | Myofibromatosis, infantile, 1 | Enrichment | PDGFRB | 1.75 |
| 312 | Thanatophoric dysplasia, type ii | Enrichment | FGFR3 | 1.75 |
| 313 | Myopathy, scapulohumeroperoneal | Enrichment | ACTA1 | 1.75 |
| 314 | Lethal congenital contracture syndrome 2 | Enrichment | ERBB3 | 1.75 |
| 315 | Gist-plus syndrome | Enrichment | PDGFRA | 1.75 |
| 316 | Camptodactyly, tall stature, and hearing loss syndrome | Enrichment | FGFR3 | 1.75 |
| 317 | Bent bone dysplasia syndrome 1 | Enrichment | FGFR2 | 1.75 |
| 318 | Megacystis-microcolon-intestinal hypoperistalsis syndrome 5 | Enrichment | ACTG2 | 1.75 |
| 319 | Visceral neuropathy, familial, 2, autosomal recessive | Enrichment | ERBB2 | 1.75 |
| 320 | Neurodevelopmental disorder with hypotonia and dysmorphic facies | Enrichment | GNB2 | 1.75 |
| 321 | Developmental and epileptic encephalopathy 58 | Enrichment | NTRK2 | 1.75 |
| 322 | Neurodevelopmental disorder with structural brain anomalies and dysmorphic facies | Enrichment | RAC3 | 1.75 |
| 323 | Fetomaternal alloimmune thrombocytopenia 2 | Enrichment | ITGA2B | 1.75 |
| 324 | Congenital smooth muscle hamartoma, with or without hemihypertrophy | Enrichment | ACTB | 1.75 |
| 325 | Myeloid and lymphoid neoplasms associated with pdgfra rearrangement | Enrichment | PDGFRA | 1.75 |
| 326 | Immunodeficiency 73c with defective neutrophil chemotaxis and hypogammaglobulinemia | Enrichment | RAC2 | 1.75 |
| 327 | T-cell large granular lymphocyte leukemia | Enrichment | STAT3 | 1.75 |
| 328 | Lodder-merla syndrome, type 2, with developmental delay and with or without cardiac arrhythmia | Enrichment | GNB5 | 1.75 |
| 329 | Crouzon syndrome with acanthosis nigricans | Enrichment | FGFR3 | 1.75 |
| 330 | Camurati-engelmann disease 2 | Enrichment | TGFB2 | 1.75 |
| 331 | Charcot-marie-tooth disease, axonal, type 2f | Enrichment | HSPB1 | 1.75 |
| 332 | Becker nevus syndrome | Enrichment | ACTB | 1.75 |
| 333 | Dystonia-deafness syndrome 1 | Enrichment | ACTB | 1.75 |
| 334 | Visceral neuropathy, familial, 3, autosomal dominant | Enrichment | ACTG2 | 1.75 |
| 335 | Colorectal cancer, hereditary nonpolyposis, type 6 | Enrichment | TGFBR2 | 1.75 |
| 336 | Congenital myopathy 2b, severe infantile, autosomal recessive | Enrichment | ACTA1 | 1.75 |
| 337 | Basal ganglia calcification, idiopathic, 4 | Enrichment | PDGFRB | 1.75 |
| 338 | Dystonia 25 | Enrichment | GNAL | 1.75 |
| 339 | Amyotrophic lateral sclerosis 19 | Enrichment | ERBB4 | 1.75 |
| 340 | Achromatopsia 7 | Enrichment | ATF6 | 1.75 |
| 341 | Myeloid and lymphoid neoplasms associated with pdgfrb rearrangement | Enrichment | PDGFRB | 1.75 |
| 342 | Charcot-marie-tooth disease, dominant intermediate f | Enrichment | GNB4 | 1.75 |
| 343 | Autosomal dominant familial visceral neuropathy | Enrichment | ACTG2 | 1.75 |
| 344 | Obesity, hyperphagia, and developmental delay | Enrichment | NTRK2 | 1.75 |
| 345 | Macular dystrophy, patterned, 3 | Enrichment | MAPKAPK3 | 1.75 |
| 346 | Achondroplasia, severe, with developmental delay and acanthosis nigricans | Enrichment | FGFR3 | 1.75 |
| 347 | Kosaki overgrowth syndrome | Enrichment | PDGFRB | 1.75 |
| 348 | Hartsfield syndrome | Enrichment | FGFR1 | 1.75 |
| 349 | Loeys-dietz syndrome 5 | Enrichment | TGFB3 | 1.75 |
| 350 | Autoimmune disease, multisystem, infantile-onset, 1 | Enrichment | STAT3 | 1.75 |
| 351 | Ectodermal dysplasia with facial dysmorphism and acral, ocular, and brain anomalies | Enrichment | RHOA | 1.75 |
| 352 | Intellectual developmental disorder, autosomal dominant 42 | Enrichment | GNB1 | 1.75 |
| 353 | Congenital myopathy 2c, severe infantile, autosomal dominant | Enrichment | ACTA1 | 1.75 |
| 354 | Sick sinus syndrome 4 | Enrichment | GNB2 | 1.75 |
| 355 | Thrombocytopenia 8, with dysmorphic features and developmental delay | Enrichment | ACTB | 1.75 |
| 356 | Short sleep, familial natural, 2 | Enrichment | ADRB1 | 1.75 |
| 357 | Ocular pterygium-digital keloid dysplasia syndrome | Enrichment | PDGFRB | 1.75 |
| 358 | Linear hypopigmentation and craniofacial asymmetry with acral, ocular and brain anomalies | Enrichment | RHOA | 1.75 |
| 359 | Immunodeficiency 73b with defective neutrophil chemotaxis and lymphopenia | Enrichment | RAC2 | 1.75 |
| 360 | Immunodeficiency 129 | Enrichment | RHOH | 1.75 |
| 361 | T-b+ severe combined immunodeficiency due to jak3 deficiency | Enrichment | JAK3 | 1.75 |
| 362 | Amelogenesis imperfecta, type ih | Enrichment | ITGB6 | 1.75 |
| 363 | Lacrimoauriculodentodigital syndrome 2 | Enrichment | FGFR3 | 1.75 |
| 364 | Baraitser-winter syndrome | Enrichment | ACTB | 1.75 |
| 365 | Lipodystrophy, familial partial, type 8 | Enrichment | ADRA2A | 1.75 |
| 366 | T-cell immunodeficiency with epidermodysplasia verruciformis | Enrichment | RHOH | 1.75 |
| 367 | Stat3-related early-onset multisystem autoimmune disease | Enrichment | STAT3 | 1.75 |
| 368 | Fetomaternal alloimmune thrombocytopenia 3 | Enrichment | ITGA2 | 1.75 |
| 369 | Immune dysregulation, neurodevelopmental defects, and colitis | Enrichment | ITGAV | 1.75 |
| 370 | Zebra body myopathy | Enrichment | ACTA1 | 1.75 |
| 371 | Infantile lad-like disease due to rac2 deficiency | Enrichment | RAC2 | 1.75 |
| 372 | Fgfr3-related chondrodysplasia | Enrichment | FGFR3 | 1.75 |
| 373 | Congenital smooth muscle hamartoma | Enrichment | ACTB | 1.75 |
| 374 | Reticular dysgenesis-like severe combined immunodeficiency | Enrichment | RAC2 | 1.75 |
| 375 | Developmental malformations-deafness-dystonia syndrome | Enrichment | ACTB | 1.75 |
| 376 | Camptodactyly-tall stature-scoliosis-hearing loss syndrome | Enrichment | FGFR3 | 1.75 |
| 377 | Actin-accumulation myopathy | Enrichment | ACTA1 | 1.75 |
| 378 | Microcephaly-corpus callosum and cerebellar vermis hypoplasia-facial dysmorphism-intellectual disability syndrom | Enrichment | RAC1 | 1.75 |
| 379 | Hartsfield-bixler-demyer syndrome | Enrichment | FGFR1 | 1.75 |
| 380 | Kaposiform hemangioendothelioma | Enrichment | GNA14 | 1.75 |
| 381 | Chronic lymphoproliferative disorder of natural killer cells | Enrichment | STAT3 | 1.75 |
| 382 | Mendelian susceptibility to mycobacterial diseases due to partial jak1 deficiency | Enrichment | JAK1 | 1.75 |
| 383 | Myopathic intestinal pseudoobstruction | Enrichment | ACTG2 | 1.75 |
| 384 | Rac2-related combined immunodeficiency-bronchiectasis-cancer-predisposing syndrome | Enrichment | RAC2 | 1.75 |
| 385 | Non-syndromic unicoronal craniosynostosis | Enrichment | FGFR2 | 1.75 |
| 386 | Serous carcinoma of the corpus uteri | Enrichment | ERBB2 | 1.75 |
| 387 | Actg2 visceral myopathy | Enrichment | ACTG2 | 1.75 |
| 388 | Microcephaly | Enrichment | CAMK2B, EP300, HDAC8, IGF1R, MAPK1 | 1.72 |
| 389 | Connective tissue disease | Enrichment | ACTA2, FGFR3, TGFBR2 | 1.71 |
| 390 | Spinocerebellar ataxia 29 | Enrichment | ITPR1 | 1.71 |
| 391 | Fibromatosis, gingival, 1 | Enrichment | SOS1 | 1.71 |
| 392 | Costello syndrome | Enrichment | HRAS | 1.71 |
| 393 | Glycogen storage disease 0, liver | Enrichment | GYS2 | 1.71 |
| 394 | Timothy syndrome | Enrichment | CACNA1C | 1.71 |
| 395 | Night blindness, congenital stationary, type 2a | Enrichment | CACNA1F | 1.71 |
| 396 | Immunodeficiency 33 | Enrichment | IKBKG | 1.71 |
| 397 | Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 2 | Enrichment | PIK3R5 | 1.71 |
| 398 | Histiocytoma, angiomatoid fibrous | Enrichment | CREB1 | 1.71 |
| 399 | Alternating hemiplegia of childhood 1 | Enrichment | CACNA1A | 1.71 |
| 400 | Ectodermal dysplasia and immunodeficiency 2 | Enrichment | NFKBIA | 1.71 |
| 401 | Ventricular tachycardia, catecholaminergic polymorphic, 4 | Enrichment | CALM1 | 1.71 |
| 402 | Silver-russell syndrome 3 | Enrichment | IGF2 | 1.71 |
| 403 | Spermatogenic failure 17 | Enrichment | PLCZ1 | 1.71 |
| 404 | Immunodeficiency, common variable, 12, with autoimmunity | Enrichment | NFKB1 | 1.71 |
| 405 | Long qt syndrome 14 | Enrichment | CALM1 | 1.71 |
| 406 | Long qt syndrome 8 | Enrichment | CACNA1C | 1.71 |
| 407 | Leukoencephalopathy with vanishing white matter 4 | Enrichment | EIF2B4 | 1.71 |
| 408 | Noonan syndrome 12 | Enrichment | RRAS2 | 1.71 |
| 409 | Cebalid syndrome | Enrichment | MTOR | 1.71 |
| 410 | Glycogen storage disease 0, muscle | Enrichment | GYS1 | 1.71 |
| 411 | Senior-loken syndrome 7 | Enrichment | AKT3 | 1.71 |
| 412 | Ocular melanoma | Enrichment | PLCB4 | 1.71 |
| 413 | Bardet-biedl syndrome 16 | Enrichment | AKT3 | 1.71 |
| 414 | Congenital disorder of glycosylation, type iw, autosomal dominant | Enrichment | CACNA1D | 1.71 |
| 415 | Smith-kingsmore syndrome | Enrichment | MTOR | 1.71 |
| 416 | Glucosephosphate dehydrogenase deficiency | Enrichment | IKBKG | 1.71 |
| 417 | Neurodevelopmental disorder with seizures and nonepileptic hyperkinetic movements | Enrichment | CACNA1B | 1.71 |
| 418 | Glycogen storage disorder due to hepatic glycogen synthase deficiency | Enrichment | GYS2 | 1.71 |
| 419 | Joint contractures, osteochondromas, and b-cell lymphoma | Enrichment | NFATC2 | 1.71 |
| 420 | Vacterl with hydrocephalus | Enrichment | PTEN | 1.71 |
| 421 | Growth delay due to insulin-like growth factor type 1 deficiency | Enrichment | IGF1 | 1.71 |
| 422 | Glycogen storage disease due to muscle and heart glycogen synthase deficiency | Enrichment | GYS1 | 1.71 |
| 423 | Common variable immunodeficiency 12 | Enrichment | NFKB1 | 1.71 |
| 424 | Juvenile polyposis of infancy | Enrichment | PTEN | 1.71 |
| 425 | Silver-russell syndrome due to an imprinting defect of 11p15 | Enrichment | IGF2 | 1.71 |
| 426 | Tafro syndrome | Enrichment | MAP2K2 | 1.71 |
| 427 | Progressive bulbar palsy | Enrichment | CACNA1A | 1.71 |
| 428 | Wooly hair nevus | Enrichment | HRAS | 1.71 |
| 429 | Silver-russell syndrome due to 11p15 microduplication | Enrichment | IGF2 | 1.71 |
| 430 | Heart, malformation of | Enrichment | GATA4, MAPK1 | 1.68 |
| 431 | Patent foramen ovale | Enrichment | GATA4, NKX2-5 | 1.68 |
| 432 | Congenital nervous system abnormality | Enrichment | CACNA1A, CAMK2B, EIF2B2, PTEN | 1.68 |
| 433 | Nervous system disease | Enrichment | CACNA1A, CAMK2B, EIF2B2, PTEN | 1.68 |
| 434 | Acute promyelocytic leukemia | Enrichment | PRKAR1A, STAT3 | 1.66 |
| 435 | Cardiomyopathy, familial hypertrophic, 1 | Enrichment | CACNA1C, RAF1 | 1.63 |
| 436 | Pseudohypoparathyroidism, type ia | Enrichment | GNAS | 1.61 |
| 437 | Scoliosis, isolated 1 | Enrichment | MAPK7 | 1.61 |
| 438 | Amelogenesis imperfecta, type ig | Enrichment | PRKAR1A | 1.61 |
| 439 | Pituitary adenoma 4, acth-secreting | Enrichment | GNAI2 | 1.61 |
| 440 | Cutis marmorata telangiectatica congenita | Enrichment | GNA11 | 1.61 |
| 441 | Thumb deformity | Enrichment | CREBBP | 1.61 |
| 442 | Pseudopseudohypoparathyroidism | Enrichment | GNAS | 1.61 |
| 443 | Bleeding disorder, platelet-type, 19 | Enrichment | PRKACG | 1.61 |
| 444 | Syndactyly, type iii | Enrichment | HDAC8 | 1.61 |
| 445 | Marbach-schaaf neurodevelopmental syndrome | Enrichment | PRKAR1B | 1.61 |
| 446 | Menke-hennekam syndrome 2 | Enrichment | EP300 | 1.61 |
| 447 | Usher syndrome, type iv | Enrichment | PRKAR1A | 1.61 |
| 448 | Wilson-turner syndrome | Enrichment | HDAC8 | 1.61 |
| 449 | Acute myeloid leukemia with kat6a-crebbp fusion | Enrichment | CREBBP | 1.61 |
| 450 | Autosomal dominant hypocalcemia | Enrichment | GNA11 | 1.61 |
| 451 | Acrodysostosis | Enrichment | PRKAR1A | 1.61 |
| 452 | Pseudohypoparathyroidism | Enrichment | GNAS | 1.61 |
| 453 | 46,xy sex reversal 3 | Enrichment | GATA4 | 1.61 |
| 454 | Body mass index quantitative trait locus 19 | Enrichment | ADCY3 | 1.61 |
| 455 | Fibrolamellar carcinoma | Enrichment | PRKACA | 1.61 |
| 456 | Ciliary dyskinesia, primary, 18 | Enrichment | PRKAR1B | 1.61 |
| 457 | Hypopituitarism | Enrichment | GNAI2 | 1.61 |
| 458 | Familial isolated congenital asplenia | Enrichment | NKX2-5 | 1.61 |
| 459 | Isolated primary pigmented nodular adrenocortical disease | Enrichment | PRKAR1A | 1.61 |
| 460 | Deletion 5q35 | Enrichment | NKX2-5 | 1.61 |
| 461 | Acth-independent macronodular adrenal hyperplasia | Enrichment | GNAS | 1.61 |
| 462 | Phakomatosis cesioflammea | Enrichment | GNA11 | 1.61 |
| 463 | Aortic aneurysm, familial thoracic 1 | Enrichment | GATA4, MYLK | 1.59 |
| 464 | Congenital myopathy 4a, autosomal dominant | Enrichment | ACTA1, ITGA7 | 1.54 |
| 465 | Hydrocephalus | Enrichment | FGFR2, PDGFRB | 1.54 |
| 466 | Lynch syndrome | Enrichment | KRAS, TGFBR2 | 1.54 |
| 467 | Van der woude syndrome 1 | Enrichment | CACNA1E | 1.53 |
| 468 | Ataxia-telangiectasia | Enrichment | BRAF | 1.53 |
| 469 | Gillespie syndrome | Enrichment | ITPR1 | 1.53 |
| 470 | Nuchal bleb, familial | Enrichment | SOS1 | 1.53 |
| 471 | Nasopharyngeal carcinoma | Enrichment | NFKBIA | 1.53 |
| 472 | Nephrotic syndrome, type 3 | Enrichment | PLCE1 | 1.53 |
| 473 | Immunodeficiency 14a with lymphoproliferation, autosomal dominant | Enrichment | PIK3R1 | 1.53 |
| 474 | Miller-dieker lissencephaly syndrome | Enrichment | YWHAE | 1.53 |
| 475 | Chromosome 17p13.3, centromeric, duplication syndrome | Enrichment | YWHAE | 1.53 |
| 476 | Immunodeficiency 14 | Enrichment | PIK3R1 | 1.53 |
| 477 | Laryngeal squamous cell carcinoma | Enrichment | PTEN | 1.53 |
| 478 | Growth delay due to insulin-like growth factor i resistance | Enrichment | IGF1R | 1.53 |
| 479 | Melanoma of soft tissue | Enrichment | CREB1 | 1.53 |
| 480 | Thyrotoxic periodic paralysis | Enrichment | CACNA1S | 1.53 |
| 481 | Beckwith-wiedemann syndrome due to imprinting defect of 11p15 | Enrichment | IGF2 | 1.53 |
| 482 | Hereditary episodic ataxia | Enrichment | CACNA1A | 1.53 |
| 483 | Cone-rod dystrophy 2 | Enrichment | ATF6, CACNA1F, CACNA2D4, ITGA4 | 1.47 |
| 484 | Leukemia, acute myeloid | Enrichment | JAK2, KRAS, NRAS | 1.46 |
| 485 | Familial atrial fibrillation | Enrichment | GATA4, NKX2-5 | 1.45 |
| 486 | Leukocyte adhesion deficiency, type i | Enrichment | ITGB2 | 1.45 |
| 487 | Myeloproliferative disorder, chronic, with eosinophilia | Enrichment | PDGFRB | 1.45 |
| 488 | Camurati-engelmann disease 1 | Enrichment | TGFB1 | 1.45 |
| 489 | Insensitivity to pain, congenital, with anhidrosis | Enrichment | NTRK1 | 1.45 |
| 490 | Visceral neuropathy, familial, 1, autosomal recessive | Enrichment | ERBB3 | 1.45 |
| 491 | Cervical cancer | Enrichment | FGFR3 | 1.45 |
| 492 | Aortic aneurysm, familial thoracic 2 | Enrichment | ACTA2 | 1.45 |
| 493 | Microvascular complications of diabetes 5 | Enrichment | TGFBR2 | 1.45 |
| 494 | Hyperinsulinemic hypoglycemia, familial, 4 | Enrichment | INSR | 1.45 |
| 495 | Aural atresia, congenital | Enrichment | FGFR2 | 1.45 |
| 496 | Deafness, autosomal dominant 20 | Enrichment | ACTG1 | 1.45 |
| 497 | Keratosis, seborrheic | Enrichment | FGFR3 | 1.45 |
| 498 | Smooth muscle dysfunction syndrome | Enrichment | ACTA2 | 1.45 |
| 499 | Leukocyte adhesion deficiency, type iii | Enrichment | ITGB2 | 1.45 |
| 500 | Aortic aneurysm, familial thoracic 6 | Enrichment | ACTA2 | 1.45 |
| 501 | Neuronopathy, distal hereditary motor, autosomal dominant 3 | Enrichment | HSPB1 | 1.45 |
| 502 | Baraitser-winter syndrome 2 | Enrichment | ACTG1 | 1.45 |
| 503 | Angioma, tufted | Enrichment | GNA14 | 1.45 |
| 504 | Moyamoya disease 5 | Enrichment | ACTA2 | 1.45 |
| 505 | Night blindness, congenital stationary, type 1h | Enrichment | GNB3 | 1.45 |
| 506 | Thrombocythemia 3 | Enrichment | JAK2 | 1.45 |
| 507 | Pain sensitivity quantitative trait locus 1 | Enrichment | NTRK1 | 1.45 |
| 508 | Antley-bixler syndrome without genital anomalies or disordered steroidogenesis | Enrichment | FGFR2 | 1.45 |
| 509 | Intellectual developmental disorder, autosomal dominant 48 | Enrichment | RAC1 | 1.45 |
| 510 | Epidermolysis bullosa, junctional 5a, intermediate | Enrichment | ITGB4 | 1.45 |
| 511 | Inflammatory bowel disease, immunodeficiency, and encephalopathy | Enrichment | TGFB1 | 1.45 |
| 512 | Infantile myofibromatosis | Enrichment | PDGFRB | 1.45 |
| 513 | Epidermolysis bullosa, junctional 7, with interstitial lung disease and nephrotic syndrome | Enrichment | ITGA3 | 1.45 |
| 514 | Split hand-foot malformation | Enrichment | FGFR2 | 1.45 |
| 515 | Rosette-forming glioneuronal tumor | Enrichment | FGFR1 | 1.45 |
| 516 | Congenital mesoblastic nephroma | Enrichment | NTRK3 | 1.45 |
| 517 | Camurati-engelmann disease | Enrichment | TGFB1 | 1.45 |
| 518 | Autoinflammation, immune dysregulation, and eosinophilia | Enrichment | JAK1 | 1.45 |
| 519 | Cervix carcinoma | Enrichment | FGFR3 | 1.45 |
| 520 | Fibrosarcoma | Enrichment | NTRK3 | 1.45 |
| 521 | Lodder-merla syndrome, type 1, with impaired intellectual development and cardiac arrhythmia | Enrichment | GNB5 | 1.45 |
| 522 | Polycythemia | Enrichment | JAK2 | 1.45 |
| 523 | Interfrontal craniofaciosynostosis | Enrichment | FGFR1 | 1.45 |
| 524 | Localized junctional epidermolysis bullosa, non-herlitz type | Enrichment | ITGB4 | 1.45 |
| 525 | Autosomal dominant nonsyndromic deafness | Enrichment | FGFR2 | 1.45 |
| 526 | Chronic eosinophilic leukemia | Enrichment | PDGFRA | 1.45 |
| 527 | Hypereosinophilic syndrome | Enrichment | JAK2 | 1.45 |
| 528 | B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormality | Enrichment | PDGFRA | 1.45 |
| 529 | Intestinal obstruction | Enrichment | ACTG2 | 1.45 |
| 530 | Cerebral visual impairment | Enrichment | GNB1 | 1.45 |
| 531 | Dandy-walker syndrome | Enrichment | BRAF, PDGFRB | 1.44 |
| 532 | Mccune-albright syndrome | Enrichment | GNAS | 1.43 |
| 533 | Frontometaphyseal dysplasia | Enrichment | MAP3K7 | 1.43 |
| 534 | Intraocular pressure quantitative trait locus | Enrichment | CREBBP | 1.43 |
| 535 | Cushing syndrome due to bilateral macronodular adrenocortical disease | Enrichment | GNAS | 1.43 |
| 536 | Migraine, familial hemiplegic, 1 | Enrichment | CACNA1A | 1.41 |
| 537 | Spinocerebellar ataxia 6 | Enrichment | CACNA1A | 1.41 |
| 538 | Thyroid cancer, nonmedullary, 1 | Enrichment | BRAF | 1.41 |
| 539 | Aland island eye disease | Enrichment | CACNA1F | 1.41 |
| 540 | Developmental and epileptic encephalopathy 2 | Enrichment | CACNA1A | 1.41 |
| 541 | Neurofibromatosis-noonan syndrome | Enrichment | MAP2K2 | 1.41 |
| 542 | Ventricular fibrillation, paroxysmal familial, 1 | Enrichment | CACNA1C | 1.41 |
| 543 | Chromosome 22q11.2 deletion syndrome, distal | Enrichment | MAPK1 | 1.41 |
| 544 | Focal cortical dysplasia, type ii | Enrichment | MTOR | 1.41 |
| 545 | Spinocerebellar ataxia 15 | Enrichment | ITPR1 | 1.41 |
| 546 | Developmental and epileptic encephalopathy 12 | Enrichment | PLCB1 | 1.41 |
| 547 | Developmental and epileptic encephalopathy 42 | Enrichment | CACNA1A | 1.41 |
| 548 | Cerebellar atrophy with seizures and variable developmental delay | Enrichment | CACNA2D2 | 1.41 |
| 549 | Developmental and epileptic encephalopathy 52 | Enrichment | CACNA1A | 1.41 |
| 550 | Lung sarcomatoid carcinoma | Enrichment | KRAS | 1.41 |
| 551 | Craniopharyngioma | Enrichment | BRAF | 1.41 |
| 552 | Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia | Enrichment | YWHAZ | 1.41 |
| 553 | Pilocytic astrocytoma | Enrichment | KRAS | 1.41 |
| 554 | Newborn respiratory distress syndrome | Enrichment | BRAF | 1.41 |
| 555 | Epidermolytic nevus | Enrichment | HRAS | 1.41 |
| 556 | Malignant hyperthermia | Enrichment | CACNA1S | 1.41 |
| 557 | Episodic ataxia | Enrichment | CACNA1A | 1.41 |
| 558 | Familial or sporadic hemiplegic migraine | Enrichment | CACNA1A | 1.41 |
| 559 | Silver-russell syndrome due to a point mutation | Enrichment | IGF2 | 1.41 |
| 560 | Isolated focal cortical dysplasia type ii | Enrichment | MTOR | 1.41 |
| 561 | Gingival fibromatosis | Enrichment | SOS1 | 1.41 |
| 562 | Male infertility due to gonadal dysgenesis or sperm disorder | Enrichment | SOS2 | 1.41 |
| 563 | Tetralogy of fallot | Enrichment | GATA4, NKX2-5 | 1.38 |
| 564 | Gastric cancer | Enrichment | ERBB2, FGFR2, KRAS | 1.38 |
| 565 | Congenital myopathy | Enrichment | ACTA1, CACNA1S | 1.35 |
| 566 | Ehlers-danlos syndrome | Enrichment | TGFB2, TGFBR2 | 1.35 |
| 567 | Eye disease | Enrichment | CACNA1F, CACNA2D4 | 1.33 |
| 568 | Episodic ataxia, type 2 | Enrichment | CACNA1A | 1.31 |
| 569 | Anemia, congenital, nonspherocytic hemolytic, 1 | Enrichment | IKBKG | 1.31 |
| 570 | Macrocephaly/autism syndrome | Enrichment | PTEN | 1.31 |
| 571 | Heart conduction disease | Enrichment | CACNA1C | 1.31 |
| 572 | Amblyopia | Enrichment | CACNA1F | 1.31 |
| 573 | Cardiac arrest | Enrichment | CACNA2D1 | 1.31 |
| 574 | Hemangioma | Enrichment | PTEN | 1.31 |
| 575 | Acute megakaryocytic leukemia | Enrichment | PTEN | 1.31 |
| 576 | Congenital short qt syndrome | Enrichment | CACNA2D1 | 1.31 |
| 577 | Endometrial stromal sarcoma | Enrichment | YWHAE | 1.31 |
| 578 | Kaposi sarcoma | Enrichment | IL6 | 1.31 |
| 579 | Pseudohypoparathyroidism, type ib | Enrichment | GNAS | 1.31 |
| 580 | Carney complex variant | Enrichment | PRKAR1A | 1.31 |
| 581 | Arrhythmogenic right ventricular dysplasia, familial, 10 | Enrichment | PRKAR1A | 1.31 |
| 582 | Achromatopsia 4 | Enrichment | GNAI3 | 1.31 |
| 583 | Hereditary ataxia | Enrichment | PRKCG | 1.31 |
| 584 | Hereditary progressive cardiac conduction defect | Enrichment | NKX2-5 | 1.31 |
| 585 | Transposition of the great arteries | Enrichment | GATA4 | 1.31 |
| 586 | Systemic-onset juvenile idiopathic arthritis | Enrichment | IL6 | 1.31 |
| 587 | Developmental and epileptic encephalopathy | Enrichment | CACNA1E, CACNA2D2 | 1.31 |
| 588 | Craniosynostosis | Enrichment | FGFR2, FGFR3 | 1.31 |
| 589 | Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-negative, nk cell-negative, due to adenosine deaminase deficiency | Enrichment | JAK3 | 1.28 |
| 590 | Achondroplasia | Enrichment | FGFR3 | 1.28 |
| 591 | Hypogonadotropic hypogonadism 2 with or without anosmia | Enrichment | FGFR1 | 1.28 |
| 592 | Larsen syndrome | Enrichment | FGFR3 | 1.28 |
| 593 | Thyroid carcinoma, familial medullary | Enrichment | NTRK1 | 1.28 |
| 594 | Polycythemia vera | Enrichment | JAK2 | 1.28 |
| 595 | Aortic aneurysm, familial thoracic 7 | Enrichment | MYLK | 1.28 |
| 596 | Muscular dystrophy, congenital, due to integrin alpha-7 deficiency | Enrichment | ITGA7 | 1.28 |
| 597 | Chromosome 8p11 myeloproliferative syndrome | Enrichment | FGFR1 | 1.28 |
| 598 | Neonatal nephrocutaneous inflammatory syndrome | Enrichment | EGFR | 1.28 |
| 599 | Epidermolysis bullosa, junctional 6, with pyloric atresia | Enrichment | ITGA6 | 1.28 |
| 600 | Primary polycythemia | Enrichment | EPOR | 1.28 |
| 601 | Bacteremia 2 | Enrichment | MAPKAPK3 | 1.28 |
| 602 | Hyper ige syndrome | Enrichment | STAT3 | 1.28 |
| 603 | Hamartoma | Enrichment | FGFR3 | 1.28 |
| 604 | Testicular germ cell cancer | Enrichment | FGFR3 | 1.28 |
| 605 | Bleeding disorder, platelet-type, 24 | Enrichment | ITGB3 | 1.28 |
| 606 | Neonatal inflammatory skin and bowel disease | Enrichment | EGFR | 1.28 |
| 607 | Alopecia - intellectual disability syndrome | Enrichment | ITGB6 | 1.28 |
| 608 | Testicular cancer | Enrichment | FGFR3 | 1.28 |
| 609 | Centronuclear myopathy | Enrichment | ACTA1, CACNA1S | 1.27 |
| 610 | Dilated cardiomyopathy | Enrichment | ACTA1, BRAF, NKX2-5, RAF1 | 1.25 |
| 611 | Hypokalemic periodic paralysis, type 1 | Enrichment | CACNA1S | 1.24 |
| 612 | Cowden syndrome 1 | Enrichment | PTEN | 1.24 |
| 613 | Hemihyperplasia, isolated | Enrichment | IGF2 | 1.24 |
| 614 | Wilms tumor 5 | Enrichment | BRAF | 1.24 |
| 615 | Ventricular tachycardia, catecholaminergic polymorphic, 1, with or without atrial dysfunction and/or dilated cardiomyopathy | Enrichment | CALM1 | 1.24 |
| 616 | Spinocerebellar ataxia, autosomal recessive 16 | Enrichment | ITPR1 | 1.24 |
| 617 | Kidney clear cell sarcoma | Enrichment | YWHAE | 1.24 |
| 618 | Childhood absence epilepsy | Enrichment | CACNA1H | 1.24 |
| 619 | Capillary malformations, congenital | Enrichment | GNA11 | 1.22 |
| 620 | Rheumatoid arthritis, systemic juvenile | Enrichment | IL6 | 1.22 |
| 621 | Rubinstein-taybi syndrome 2 | Enrichment | EP300 | 1.22 |
| 622 | Ventricular septal defect 1 | Enrichment | GATA4 | 1.22 |
| 623 | Congenital heart defects, multiple types, 4 | Enrichment | GATA4 | 1.22 |
| 624 | Persistent truncus arteriosus | Enrichment | NKX2-5 | 1.22 |
| 625 | Silver-russell syndrome 1 | Enrichment | IGF2 | 1.17 |
| 626 | Squamous cell carcinoma, head and neck | Enrichment | PTEN | 1.17 |
| 627 | Brugada syndrome 1 | Enrichment | CACNA2D1 | 1.17 |
| 628 | Renal cell carcinoma, papillary, 1 | Enrichment | MTOR | 1.17 |
| 629 | Megacolon | Enrichment | AKT3 | 1.17 |
| 630 | Common variable immunodeficiency | Enrichment | NFKB1 | 1.17 |
| 631 | Amelogenesis imperfecta, type iiia | Enrichment | ITGB6 | 1.15 |
| 632 | Nemaline myopathy 2 | Enrichment | ACTA1 | 1.15 |
| 633 | Spastic paraplegia 17, autosomal dominant | Enrichment | GNG3 | 1.15 |
| 634 | Autoimmune lymphoproliferative syndrome | Enrichment | ACTA2 | 1.15 |
| 635 | Budd-chiari syndrome | Enrichment | JAK2 | 1.15 |
| 636 | Lipodystrophy, congenital generalized, type 2 | Enrichment | GNG3 | 1.15 |
| 637 | Epidermolysis bullosa simplex 5c, with pyloric atresia | Enrichment | ITGB4 | 1.15 |
| 638 | Retinitis pigmentosa 26 | Enrichment | ITGA4 | 1.15 |
| 639 | Barrett esophagus | Enrichment | ERBB2 | 1.15 |
| 640 | Aminoacylase 1 deficiency | Enrichment | ACTB | 1.15 |
| 641 | Aortic aneurysm | Enrichment | TGFBR1 | 1.15 |
| 642 | Tuberculosis | Enrichment | MAPKAPK3 | 1.15 |
| 643 | Adenosine deaminase deficiency | Enrichment | JAK3 | 1.15 |
| 644 | Non-syndromic bicoronal craniosynostosis | Enrichment | FGFR3 | 1.15 |
| 645 | Intermediate nemaline myopathy | Enrichment | ACTA1 | 1.15 |
| 646 | Familial sick sinus syndrome | Enrichment | GNB2 | 1.15 |
| 647 | Pseudomyogenic hemangioendothelioma | Enrichment | ACTB | 1.15 |
| 648 | Left ventricular noncompaction | Enrichment | NKX2-5, RAF1 | 1.15 |
| 649 | Conotruncal heart malformations | Enrichment | NKX2-5 | 1.14 |
| 650 | Type 1 diabetes mellitus | Enrichment | IL6 | 1.14 |
| 651 | Renal tubular dysgenesis | Enrichment | AGT | 1.14 |
| 652 | Adrenocortical carcinoma | Enrichment | PRKAR1A | 1.14 |
| 653 | Double outlet right ventricle | Enrichment | NKX2-5 | 1.14 |
| 654 | Hypertrichosis | Enrichment | CREBBP | 1.14 |
| 655 | Lymphoma, non-hodgkin, familial | Enrichment | BRAF | 1.12 |
| 656 | Alternating hemiplegia of childhood | Enrichment | CACNA1A | 1.12 |
| 657 | Catecholaminergic polymorphic ventricular tachycardia 1 | Enrichment | CALM1 | 1.12 |
| 658 | Difference of sex development | Enrichment | CACNA1A | 1.12 |
| 659 | Hydrops fetalis, nonimmune | Enrichment | ACTA1, HRAS | 1.10 |
| 660 | Hypothyroidism, congenital, nongoitrous, 2 | Enrichment | NKX2-5 | 1.08 |
| 661 | Myelofibrosis | Enrichment | SRC | 1.08 |
| 662 | Brachydactyly | Enrichment | GNAS | 1.08 |
| 663 | Strabismus | Enrichment | CACNA1A, GNB1 | 1.07 |
| 664 | Cardiomyopathy, familial hypertrophic, 4 | Enrichment | BRAF | 1.07 |
| 665 | Nephrotic syndrome, type 1 | Enrichment | PLCE1 | 1.07 |
| 666 | Coronary heart disease 5 | Enrichment | IKBKG | 1.07 |
| 667 | Developmental and epileptic encephalopathy 14 | Enrichment | PLCB1 | 1.07 |
| 668 | Ventricular septal defect | Enrichment | BRAF | 1.07 |
| 669 | Neuronopathy, distal hereditary motor, autosomal dominant 2 | Enrichment | HSPB1 | 1.06 |
| 670 | Arrhythmogenic right ventricular dysplasia, familial, 1 | Enrichment | TGFB3 | 1.06 |
| 671 | Epidermolysis bullosa simplex 1c, localized | Enrichment | ITGB4 | 1.06 |
| 672 | Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-negative | Enrichment | JAK3 | 1.06 |
| 673 | Congenital myopathy 3 with rigid spine | Enrichment | ACTA1 | 1.06 |
| 674 | Glanzmann thrombasthenia 2 | Enrichment | ITGB3 | 1.06 |
| 675 | Myeloproliferative neoplasm | Enrichment | JAK2 | 1.06 |
| 676 | Holoprosencephaly | Enrichment | FGFR1 | 1.06 |
| 677 | Epidermolysis bullosa | Enrichment | ITGA6 | 1.06 |
| 678 | Arrhythmogenic right ventricular dysplasia 1 | Enrichment | TGFB3 | 1.06 |
| 679 | Aplasia cutis congenita | Enrichment | ITGB4 | 1.06 |
| 680 | Coloboma of choroid and retina | Enrichment | ACTG1 | 1.06 |
| 681 | Severe congenital nemaline myopathy | Enrichment | ACTA1 | 1.06 |
| 682 | Familial cerebral saccular aneurysm | Enrichment | TGFBR3 | 1.06 |
| 683 | Primary ovarian insufficiency | Enrichment | EIF2B2, JAK2, NTRK1 | 1.05 |
| 684 | Autism spectrum disorder | Enrichment | MAP2K1, MEF2C, PTEN | 1.03 |
| 685 | Ciliary dyskinesia, primary, 3 | Enrichment | NFKB1 | 1.02 |
| 686 | Polymicrogyria | Enrichment | AKT3 | 1.02 |
| 687 | Autosomal non-syndromic agammaglobulinemia | Enrichment | PIK3R1 | 1.02 |
| 688 | Hirschsprung disease 1 | Enrichment | ERBB2, ERBB3 | 1.02 |
| 689 | Severe covid-19 | Enrichment | ITGAV, JAK3 | 1.02 |
| 690 | Spastic paraplegia 4, autosomal dominant | Enrichment | GNAS | 1.02 |
| 691 | Fanconi anemia, complementation group c | Enrichment | HDAC8 | 1.02 |
| 692 | Hypoplastic left heart syndrome | Enrichment | NKX2-5 | 1.02 |
| 693 | Atrial septal defect 1 | Enrichment | TGFB2 | 0.99 |
| 694 | Epidermolysis bullosa, junctional 1a, intermediate | Enrichment | ITGB4 | 0.99 |
| 695 | Split-hand/foot malformation 1 | Enrichment | FGFR2 | 0.99 |
| 696 | Holoprosencephaly 1 | Enrichment | FGFR1 | 0.99 |
| 697 | Moyamoya disease 1 | Enrichment | ACTA2 | 0.99 |
| 698 | Testicular germ cell tumor | Enrichment | FGFR3 | 0.99 |
| 699 | Inflammatory bowel disease 25, autosomal recessive | Enrichment | TGFB1 | 0.99 |
| 700 | Familial adult myoclonic epilepsy | Enrichment | ADRA2B | 0.99 |
| 701 | Junctional epidermolysis bullosa non-herlitz type | Enrichment | ITGB4 | 0.99 |
| 702 | Intestinal pseudo-obstruction | Enrichment | ACTG2 | 0.99 |
| 703 | Il10-related early-onset inflammatory bowel disease | Enrichment | TGFB1 | 0.99 |
| 704 | Classic ehlers-danlos syndrome | Enrichment | TGFBR1 | 0.99 |
| 705 | Typical nemaline myopathy | Enrichment | ACTA1 | 0.99 |
| 706 | Migraine with or without aura 1 | Enrichment | CACNA1A | 0.99 |
| 707 | Epilepsy, myoclonic juvenile | Enrichment | CACNB4 | 0.99 |
| 708 | Epilepsy, idiopathic generalized | Enrichment | CACNA1H | 0.99 |
| 709 | Meningioma, familial | Enrichment | PTEN | 0.99 |
| 710 | Uterine corpus cancer | Enrichment | PTEN | 0.99 |
| 711 | Cornelia de lange syndrome 1 | Enrichment | HDAC8 | 0.97 |
| 712 | Charge syndrome | Enrichment | EP300 | 0.97 |
| 713 | Cornelia de lange syndrome | Enrichment | HDAC8 | 0.97 |
| 714 | Cardiac conduction defect | Enrichment | CACNA1C | 0.95 |
| 715 | Congenital long qt syndrome | Enrichment | ITPR3 | 0.95 |
| 716 | Cystic fibrosis | Enrichment | EDNRA, TGFB1 | 0.95 |
| 717 | Stroke, ischemic | Enrichment | PRKCH | 0.93 |
| 718 | Esophageal cancer | Enrichment | TGFBR2 | 0.92 |
| 719 | Gastrointestinal stromal tumor | Enrichment | PDGFRA | 0.92 |
| 720 | Neuropathy, hereditary sensory and autonomic, type v | Enrichment | NTRK1 | 0.92 |
| 721 | Essential thrombocythemia | Enrichment | JAK2 | 0.92 |
| 722 | Epidermolysis bullosa simplex | Enrichment | ITGB4 | 0.92 |
| 723 | Childhood-onset nemaline myopathy | Enrichment | ACTA1 | 0.92 |
| 724 | Premature menopause | Enrichment | EIF2B2 | 0.92 |
| 725 | Chromosome 1p36 deletion syndrome | Enrichment | PRKCZ | 0.92 |
| 726 | Protein-deficiency anemia | Enrichment | NRAS | 0.92 |
| 727 | Cakut | Enrichment | ACTG1, LIFR | 0.91 |
| 728 | Body mass index quantitative trait locus 11 | Enrichment | ADCY3, GNAS | 0.89 |
| 729 | 46,xy complete gonadal dysgenesis | Enrichment | MAP3K1 | 0.89 |
| 730 | Multiple sclerosis | Enrichment | ITPR1 | 0.89 |
| 731 | Dystonia | Enrichment | GNAL, GNB1 | 0.88 |
| 732 | Glioma susceptibility 1 | Enrichment | ERBB2 | 0.87 |
| 733 | Basal ganglia calcification, idiopathic, 1 | Enrichment | PDGFRB | 0.87 |
| 734 | Renal hypodysplasia/aplasia 1 | Enrichment | ITGA8 | 0.87 |
| 735 | Hypothyroidism | Enrichment | GNB1 | 0.87 |
| 736 | Permanent neonatal diabetes mellitus | Enrichment | STAT3 | 0.87 |
| 737 | Renal cell carcinoma, nonpapillary | Enrichment | MTOR | 0.86 |
| 738 | Myopia | Enrichment | CACNA1F | 0.86 |
| 739 | Anterior segment dysgenesis | Enrichment | ITPR1 | 0.86 |
| 740 | Familial isolated dilated cardiomyopathy | Enrichment | HAND2, RAF1 | 0.85 |
| 741 | Leukemia, acute lymphoblastic 3 | Enrichment | JAK2 | 0.82 |
| 742 | Hypogonadotropic hypogonadism | Enrichment | FGFR1 | 0.82 |
| 743 | Familial thoracic aortic aneurysm and dissection | Enrichment | MYLK | 0.82 |
| 744 | Renal agenesis, bilateral | Enrichment | ITGA8 | 0.82 |
| 745 | Melanoma, cutaneous malignant 1 | Enrichment | BRAF | 0.81 |
| 746 | Sudden infant death syndrome | Enrichment | CALM2 | 0.81 |
| 747 | Osteoporosis | Enrichment | SRC | 0.79 |
| 748 | Beckwith-wiedemann syndrome | Enrichment | IGF2 | 0.79 |
| 749 | Cat eye syndrome | Enrichment | ACTG1 | 0.78 |
| 750 | Meier-gorlin syndrome 1 | Enrichment | FGFR2 | 0.78 |
| 751 | Amelogenesis imperfecta, type ie | Enrichment | ITGB6 | 0.78 |
| 752 | Nemaline myopathy | Enrichment | ACTA1 | 0.78 |
| 753 | Achromatopsia | Enrichment | ATF6 | 0.78 |
| 754 | Primary bone dysplasia | Enrichment | FGFR3 | 0.78 |
| 755 | Polydactyly, postaxial, type a1 | Enrichment | EP300 | 0.77 |
| 756 | Corpus callosum, agenesis of | Enrichment | CREBBP | 0.77 |
| 757 | Isolated corpus callosum agenesis | Enrichment | CREBBP | 0.77 |
| 758 | Intellectual disability-hypoplastic corpus callosum-preauricular tag syndrome | Enrichment | CREBBP | 0.77 |
| 759 | Focal segmental glomerulosclerosis | Enrichment | PLCE1 | 0.74 |
| 760 | Nephrotic syndrome | Enrichment | ITGA3, PLCE1 | 0.74 |
| 761 | Pectus excavatum | Enrichment | TGFBR1 | 0.74 |
| 762 | Leukemia, acute lymphoblastic | Enrichment | GNB1 | 0.74 |
| 763 | Myelodysplastic syndrome | Enrichment | GNB1 | 0.74 |
| 764 | Osteochondrodysplasia | Enrichment | FGFR3 | 0.74 |
| 765 | West syndrome | Enrichment | NTRK2, PLCB1 | 0.73 |
| 766 | Cardiomyopathy, dilated, 1a | Enrichment | NFATC2 | 0.73 |
| 767 | Endometrial cancer | Enrichment | PTEN | 0.73 |
| 768 | Hypertension, essential | Enrichment | AGT | 0.72 |
| 769 | Septooptic dysplasia | Enrichment | FGFR1 | 0.71 |
| 770 | Renal hypodysplasia/aplasia 3 | Enrichment | FGFR3 | 0.71 |
| 771 | Inherited isolated arrhythmogenic ventricular dysplasia, biventricular variant | Enrichment | TGFB3 | 0.71 |
| 772 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-left variant | Enrichment | TGFB3 | 0.71 |
| 773 | Polycystic kidney disease | Enrichment | HDAC8 | 0.69 |
| 774 | Brittle bone disorder | Enrichment | EIF2B2 | 0.69 |
| 775 | Malaria | Enrichment | IKBKG | 0.69 |
| 776 | Neural tube defects | Enrichment | ITGB1 | 0.68 |
| 777 | Cone dystrophy | Enrichment | CACNA2D4 | 0.67 |
| 778 | Thrombocytopenia | Enrichment | ITGA2B, ITGB3 | 0.67 |
| 779 | Pancreatic cancer | Enrichment | KRAS | 0.66 |
| 780 | Hypogonadotropic hypogonadism 7 with or without anosmia | Enrichment | FGFR1 | 0.65 |
| 781 | Cleft lip/palate | Enrichment | PDGFRA | 0.65 |
| 782 | Inherited isolated arrhythmogenic cardiomyopathy, dominant-right variant | Enrichment | TGFB3 | 0.65 |
| 783 | Isolated macular dystrophy | Enrichment | ITGA4 | 0.65 |
| 784 | Autism | Enrichment | CAMK2G, CREBBP | 0.65 |
| 785 | Auditory neuropathy | Enrichment | CACNA1A | 0.64 |
| 786 | Prostate cancer | Enrichment | PTEN | 0.60 |
| 787 | Microform holoprosencephaly | Enrichment | FGFR1 | 0.60 |
| 788 | Lobar holoprosencephaly | Enrichment | FGFR1 | 0.60 |
| 789 | Scoliosis | Enrichment | CREBBP | 0.58 |
| 790 | Cleft palate, isolated | Enrichment | GNB1 | 0.58 |
| 791 | Neuromuscular disease | Enrichment | ACTA1 | 0.55 |
| 792 | Semilobar holoprosencephaly | Enrichment | FGFR1 | 0.55 |
| 793 | Normosmic congenital hypogonadotropic hypogonadism | Enrichment | FGFR1 | 0.55 |
| 794 | Familial hypertrophic cardiomyopathy | Enrichment | RAF1 | 0.55 |
| 795 | Severe combined immunodeficiency | Enrichment | IKBKB | 0.55 |
| 796 | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Enrichment | ERBB4, MEF2C | 0.55 |
| 797 | Genetic steroid-resistant nephrotic syndrome | Enrichment | PLCE1 | 0.54 |
| 798 | Lissencephaly | Enrichment | ACTG1 | 0.50 |
| 799 | Hepatoblastoma | Enrichment | FGFR3 | 0.50 |
| 800 | Attention deficit-hyperactivity disorder | Enrichment | GNB5 | 0.48 |
| 801 | Myocardial infarction | Enrichment | ITGB3 | 0.48 |
| 802 | Visceral heterotaxy | Enrichment | LEFTY2 | 0.48 |
| 803 | Tooth agenesis | Enrichment | FGFR1 | 0.48 |
| 804 | Skin disease | Enrichment | ITGB4 | 0.48 |
| 805 | Benign epilepsy with centrotemporal spikes | Enrichment | PLCB1 | 0.48 |
| 806 | Kallmann syndrome | Enrichment | FGFR1 | 0.47 |
| 807 | Centralopathic epilepsy | Enrichment | PLCB1 | 0.46 |
| 808 | Optic atrophy plus syndrome | Enrichment | CACNA1F | 0.45 |
| 809 | Complex neurodevelopmental disorder | Enrichment | CACNA1C, GNB2, RAC3 | 0.41 |
| 810 | Inherited cancer-predisposing syndrome | Enrichment | EGFR, PDGFRA, PRKAR1A | 0.37 |
| 811 | Non-syndromic x-linked intellectual disability | Enrichment | AGTR2 | 0.32 |
| 812 | Non-syndromic genetic deafness | Enrichment | ACTG1 | 0.32 |
| 813 | Fetal akinesia deformation sequence 1 | Enrichment | ACTA1 | 0.31 |
| 814 | Male infertility with azoospermia or oligozoospermia due to single gene mutation | Enrichment | GATA4 | 0.30 |
| 815 | Systemic lupus erythematosus | Enrichment | ITGAM | 0.29 |
| 816 | Myopathy | Enrichment | ACTA1 | 0.29 |
| 817 | Charcot-marie-tooth disease | Enrichment | HSPB1 | 0.28 |
| 818 | Distal arthrogryposis | Enrichment | ACTA1 | 0.27 |
| 819 | Nonsyndromic hearing loss | Enrichment | ACTG1 | 0.27 |
| 820 | Hypertelorism | Enrichment | FGFR2 | 0.21 |
| 821 | Rare autosomal dominant non-syndromic sensorineural deafness type dfna | Enrichment | ACTG1 | 0.21 |
| 822 | Primary ciliary dyskinesia | Enrichment | PRKAR1B | 0.21 |
| 823 | Retinitis pigmentosa | Enrichment | CACNA1F, CACNA2D4 | 0.21 |
| 824 | Rare autosomal recessive non-syndromic sensorineural deafness type dfnb | Enrichment | ADCY1 | 0.17 |
| 825 | Rare genetic deafness | Enrichment | ACTG1 | 0.12 |
| 826 | Hereditary retinal dystrophy | Enrichment | ATF6, CACNA1F, CACNA2D4, ITGA4 | 0.11 |
| 827 | Fundus dystrophy | Enrichment | ATF6, CACNA1F, CACNA2D4, ITGA4 | 0.11 |